Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway.

Oncotarget
Ashley VanCleaveJianning Tao

Abstract

Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the successful establishment of a new human osteosarcoma cell line, COS-33, from a patient-derived xenograft and demonstrate retention of the biological features of the original tumor. We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway. Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein. Increasing concentrations of rapamycin progressively inhibited cell proliferation in vitro. We observed significant inhibitory effects of the drug on cell migration, invasion, and colony formation in the cultured cells. Furthermore, we found that only a strong osteogenic inducer, bone morphogenetic protein-2, promoted the cells to differentiate into mature mineralizing osteoblasts, indicating that the COS-33 cell line may have impaired osteoblast differentiation. Grafted COS-3...Continue Reading

References

Jul 1, 1977·Antimicrobial Agents and Chemotherapy·A BilliauP De Somer
Sep 15, 1967·International Journal of Cancer. Journal International Du Cancer·J Pontén, E Saksela
Sep 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Michael OverholtzerArnold J Levine
Dec 4, 2004·Methods in Molecular Biology·Hong-Chen Chen
Mar 15, 2006·The Journal of Cell Biology·Christopher J LengnerStephen N Jones
Oct 27, 2006·Pediatric Blood & Cancer·Peter J HoughtonMalcolm A Smith
Jul 20, 2007·Pediatric Blood & Cancer·Peter J HoughtonMalcolm A Smith
Mar 31, 2009·International Journal of Cancer. Journal International Du Cancer·Lisa MirabelloSharon A Savage
Jun 23, 2009·Genome Research·Martin KrzywinskiMarco A Marra
Sep 30, 2009·Genes, Chromosomes & Cancer·Laura OttavianoChristopher Poremba
Aug 6, 2010·Nature·Eliezer CaloJacqueline A Lees
Apr 27, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Alexander B MohsenyAnne-Marie Cleton-Jansen
Sep 22, 2011·BMC Medical Genomics·Marieke L KuijjerAnne-Marie Cleton-Jansen
Nov 29, 2011·Cell·Peter Friedl, Stephanie Alexander
Apr 8, 2014·Cell Reports·Xiang ChenUNKNOWN St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project
Apr 29, 2014·International Journal of Cancer. Journal International Du Cancer·Emmy D G FleurenWinette T A van der Graaf
Sep 10, 2014·Cancer Cell·Jianning TaoBrendan H Lee
Dec 17, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A PerryKatherine A Janeway
Oct 25, 2016·Bone·Kirby RickelJianning Tao
Nov 5, 2016·ACS Applied Materials & Interfaces·Qingqing YaoHongli Sun
Sep 30, 2018·Cancer Discovery·Leanne C SaylesE Alejandro Sweet-Cordero
Jan 8, 2019·Oncotarget·Fang FangJianning Tao
Feb 23, 2019·Journal of the National Cancer Institute·Motonari NomuraJason T Yustein

❮ Previous
Next ❯

Citations

Mar 7, 2021·Cells·Lorena LanduzziKatia Scotlandi

❮ Previous
Next ❯

Datasets Mentioned

BETA
AH007667.2

Methods Mentioned

BETA
xenografts
xenograft
electrophoresis
PCR

Software Mentioned

SOAPFuse
Fusion
FusionCatcher
Image J
deFuse
NIH ImageJ
STAR

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.